Fresenius SE & Co. KGaA

Earnings Release • Apr 18, 2016

Forward Thinking Healthcare

Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 200,000 employees in more than 100 countries around the globe, and annual sales exceeding €25 billion, Fresenius is one of the world's leading healthcare companies.

At Fresenius, the patient always comes first. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear focus on innovation and efficiency has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions: this is how Fresenius is contributing to medical progress and better patient care.

Success in our businesses is the foundation for everything we do. Only an economically strong company can afford to make the continuing investments essential to providing high-quality yet affordable healthcare. This is how we are meeting our social responsibility and our commitment to patients, while ensuring that Fresenius remains successful over the long term.

We will continue to look ahead, finding new ways to help our patients even more and to help even more patients around the world. That is why Fresenius is Forward Thinking Healthcare. FRESENIUS GROUP IN FIGURES (U.S. GAAP)

€ millions	2015	2014	2013
Sales and Earnings
Sales	27,626	23,231	20,331
EBIT	3,958	3,158	3,045
EBIT margin	14.3%	13.6%	15.0%
Net income	1,423	1,086	1,051
Operating cash flow	3,327	2,585	2,320
Balance sheet
Total assets	43,170	39,788	32,663
Equity ratio	42%	39%	41%
Debt ratio1	2.68	3.24	2.54
Investments	2,029	3,795	3,827
Employees (December 31)	222,305	216,275	178,337
Share
Number of shares	545,727,950	541,532,600	539,084,487
Market capitalization	36,002	23,373	20,054
Per share in €:
Dividend	0.5522	0.44	0.42
Earnings	2.61	2.01	1.96

Some figures adjusted for special items

Net debt/EBITDA

2Subject to approval by the Annual General Meeting on May 13, 2016

SALES BY BUSINESS SEGMENT

€ millions	2015	2014	Change
Fresenius Medical Care	15,086	11,917	27%
Fresenius Kabi	5,950	5,146	16%
Fresenius Helios	5,578	5,244	6%
Fresenius Vamed	1,118	1,042	7%

DIALYSIS PRODUCTS, DIALYSIS SERVICES AND CARE COORDINATION

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 3,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for around 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.

KEY FIGURES

	2015 US\$ millions	2014 US\$ millions	Change
Sales	16,738	15,832	6%
EBIT	2,388	2,271	5%
Net income	1,082	1,058	2%
Operating cash flow	1,960	1,861	5%
Capital expenditure/acquisitions	1,380	2,919	-53%
R & D expenses	140	122	15%
Employees (December 31)	110,242	105,917	4%

Some figures adjusted for special items

Net income = Net income attributable to the parent company of the respective business segment

IV DRUGS, CLINICAL NUTRITION, INFUSION THERAPY, MEDICAL DEVICES/ TRANSFUSION TECHNOLOGY

Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.

KEY FIGURES

	2015 € millions	2014 € millions	Change
Sales	5,950	5,146	16%
EBIT	1,189	873	36%
Net income	669	468	43%
Operating cash flow	913	641	42%
Capital expenditure/acquisitions	389	479	-19%
R & D expenses	336	276	22%
Employees (December 31)	33,195	32,899	1%

Fresenius Helios is the largest German private hospital operator. The HELIOS Group operates more than 100 proprietary clinics with a total of more than 30,000 beds, including seven maximum care clinics in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal. A majority of Fresenius Helios clinics are acute care facilities, but the company also owns post-acute care clinics. The company's goal is to provide high-quality, stateof-the-art treatment and care in all areas and at all care levels in its hospitals. Fresenius Helios has around 70,000 employees and treats more than 4 million patients − including more than 1 million inpatients − annually.

KEY FIGURES

	2015 € millions	2014 € millions	Change
Sales	5,578	5,244	6%
EBIT	640	553	16%
Net income	483	400	21%
Operating cash flow	618	558	11%
Capital expenditure/acquisitions	376	1,090	-66%
Employees (December 31)	69,728	68,852	1%

PROJECTS AND SERVICES FOR HOSPITALS AND OTHER HEALTH CARE FACILITIES

Fresenius Vamed is a global provider of services in planning, constructing and managing health care facilities. With its approach of "everything from one source," the company offers hospitals a complete value chain to achieve and maintain efficiency at every stage: from project development, planning and turnkey construction to facility and total operational management. Headquartered in Vienna, Austria, Fresenius Vamed boasts a track record of more than 700 completed health care projects in more than 70 countries since its founding in 1982.

KEY FIGURES

	2015 € millions	2014 € millions	Change
Sales	1,118	1,042	7%
EBIT	64	59	8%
Net income	44	41	7%
Operating cash flow	53	-9	-
Capital expenditure/acquisitions	15	22	-32%
R & D expenses	904	840	8%
Employees (December 31)	8,262	7,746	7%

Latin America and Africa 6% Asia-Pacific 10% Europe 38% North America 46% SALES BY REGION

2015: €27.6 billion

EMPLOYEES BY REGION

2015: 222,305

Corporate Headquarters

Else-Kröner-Strasse 1 Bad Homburg v.d.H. Germany

Postal address

Fresenius SE & Co. KGaA 61346 Bad Homburg v.d.H. Germany

www.facebook.com/fresenius.group www.twitter.com/fresenius www.youtube.com/freseniustv

Contact for journalists

Corporate Communications T +49 6172 608-2302 F +49 6172 608-2294 pr-fre@fresenius.com

Contact for shareholders

Investor Relations T +49 6172 608-2487 F +49 6172 608-2488 ir-fre@fresenius.com

www.fresenius.com